JP7836769B2 - ベンジルオキシリン酸エステル(ホスホン酸エステル)化合物 - Google Patents

ベンジルオキシリン酸エステル(ホスホン酸エステル)化合物

Info

Publication number
JP7836769B2
JP7836769B2 JP2022562642A JP2022562642A JP7836769B2 JP 7836769 B2 JP7836769 B2 JP 7836769B2 JP 2022562642 A JP2022562642 A JP 2022562642A JP 2022562642 A JP2022562642 A JP 2022562642A JP 7836769 B2 JP7836769 B2 JP 7836769B2
Authority
JP
Japan
Prior art keywords
optionally substituted
group
alkyl
aryl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022562642A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522866A (ja
JP2023522866A5 (cg-RX-API-DMAC7.html
Inventor
リン チー
Original Assignee
リガンド・ファーマシューティカルズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リガンド・ファーマシューティカルズ・インコーポレイテッド filed Critical リガンド・ファーマシューティカルズ・インコーポレイテッド
Publication of JP2023522866A publication Critical patent/JP2023522866A/ja
Publication of JP2023522866A5 publication Critical patent/JP2023522866A5/ja
Priority to JP2025191949A priority Critical patent/JP2026032020A/ja
Application granted granted Critical
Publication of JP7836769B2 publication Critical patent/JP7836769B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4087—Esters with arylalkanols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655381—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a seven-(or more) membered ring
    • C07F9/65539—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a seven-(or more) membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2022562642A 2020-04-21 2021-04-19 ベンジルオキシリン酸エステル(ホスホン酸エステル)化合物 Active JP7836769B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025191949A JP2026032020A (ja) 2020-04-21 2025-11-12 ベンジルオキシリン酸エステル(ホスホン酸エステル)化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063013263P 2020-04-21 2020-04-21
US63/013,263 2020-04-21
PCT/US2021/027930 WO2021216431A1 (en) 2020-04-21 2021-04-19 Benzyloxy phosph(on)ate compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025191949A Division JP2026032020A (ja) 2020-04-21 2025-11-12 ベンジルオキシリン酸エステル(ホスホン酸エステル)化合物

Publications (3)

Publication Number Publication Date
JP2023522866A JP2023522866A (ja) 2023-06-01
JP2023522866A5 JP2023522866A5 (cg-RX-API-DMAC7.html) 2024-04-19
JP7836769B2 true JP7836769B2 (ja) 2026-03-27

Family

ID=78270233

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022562642A Active JP7836769B2 (ja) 2020-04-21 2021-04-19 ベンジルオキシリン酸エステル(ホスホン酸エステル)化合物
JP2025191949A Pending JP2026032020A (ja) 2020-04-21 2025-11-12 ベンジルオキシリン酸エステル(ホスホン酸エステル)化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025191949A Pending JP2026032020A (ja) 2020-04-21 2025-11-12 ベンジルオキシリン酸エステル(ホスホン酸エステル)化合物

Country Status (5)

Country Link
US (1) US12552820B2 (cg-RX-API-DMAC7.html)
EP (1) EP4139319A4 (cg-RX-API-DMAC7.html)
JP (2) JP7836769B2 (cg-RX-API-DMAC7.html)
CN (1) CN115768778A (cg-RX-API-DMAC7.html)
WO (1) WO2021216431A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019207626B2 (en) 2018-01-10 2023-10-05 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
WO2021011692A1 (en) 2019-07-17 2021-01-21 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007094135A1 (ja) 2006-02-15 2007-08-23 Gifu University オリゴヌクレオチド誘導体及びその利用
WO2014043380A1 (en) 2012-09-14 2014-03-20 Ligand Pharmaceuticals Incorporated Novel nucleotide prodrug compounds and use
WO2016138026A1 (en) 2015-02-25 2016-09-01 Ligand Pharmaceuticals, Inc. Gemcitabine derivatives
US20190015432A1 (en) 2017-07-13 2019-01-17 Emory University Lipid Disulfide Prodrugs and Uses Related Thereto
WO2019143860A1 (en) 2018-01-19 2019-07-25 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6023120B2 (ja) 1979-08-13 1985-06-05 キッコーマン株式会社 アデノシン−3′,5′−環状リン酸アルキルトリエステルの製造法
DE3027279A1 (de) 1980-07-18 1982-05-06 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Substituierte adenosin-3',5'-phosphorsaeurebenzyltriester, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
JPS61204193A (ja) 1985-03-05 1986-09-10 Takeda Chem Ind Ltd シトシンヌクレオシド類の製造法
CA1327358C (en) 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
JPH0692987A (ja) 1992-09-17 1994-04-05 Tanabe Seiyaku Co Ltd ウリジン誘導体およびその製法
AU671491B2 (en) 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US5693521A (en) 1993-04-09 1997-12-02 The Regents Of The University Of California Membrane-permeant second messengers
US5834436A (en) 1993-04-09 1998-11-10 The Regents Of The University Of California Membrane-permeant second messengers
US5866548A (en) 1993-04-09 1999-02-02 The Regents Of The University Of California Caged membrane-permeant inositol phosphates
US5476932A (en) 1994-08-26 1995-12-19 Hoffmann-La Roche Inc. Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
HRP20030047B1 (hr) 2000-07-21 2016-02-26 Gilead Sciences, Inc. Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
CA2416527C (en) 2000-08-10 2009-12-22 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2002092006A2 (en) 2001-05-16 2002-11-21 Micrologix Biotech, Inc. Nucleic acid-based compounds and methods of use thereof
KR20050035194A (ko) 2002-06-28 2005-04-15 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료용 2'-c-메틸-3'-o-l-발린에스테르 리보푸라노실 사이티딘
WO2005018330A1 (en) 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
ES2310860T3 (es) 2004-12-17 2009-01-16 Eli Lilly And Company Profarmaco amida de gemcitabina, composiciones y uso del mismo.
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
EP1915053A2 (en) 2005-08-12 2008-04-30 Merck & Co., Inc. Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives
ES2436404T3 (es) 2005-10-03 2013-12-30 University Health Network Inhibidores ODCasa para el tratamiento de malaria
JP2009531284A (ja) 2006-02-06 2009-09-03 ドクター レディズ ラボラトリーズ リミテッド ゲムシタビンの調製
FR2907786B1 (fr) 2006-10-27 2009-09-18 Univ Grenoble 1 Thionucleosides et applications pharmaceutiques
US8338593B2 (en) 2006-07-07 2012-12-25 Gilead Sciences, Inc. Modulators of toll-like receptor 7
WO2008030373A2 (en) 2006-09-01 2008-03-13 University Of Georgia Research Foundation, Inc. L- oddc prodrugs for cancer
WO2008083465A1 (en) 2007-01-08 2008-07-17 University Health Network Pyrimidine derivatives as anticancer agents
WO2008144980A1 (fr) 2007-05-25 2008-12-04 Topharman Shanghai Co., Ltd. Procédé de préparation et intermédiaires de la capécitabine
US8741858B2 (en) 2007-09-21 2014-06-03 Zhongxu Ren Oligomer-nucleoside phosphate conjugates
WO2009061781A1 (en) 2007-11-07 2009-05-14 Schering Corporation Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
KR101013312B1 (ko) 2007-11-19 2011-02-09 한미홀딩스 주식회사 카페시타빈의 제조방법 및 이에 사용되는 β-아노머가강화된 트리알킬카보네이트 화합물의 제조방법
WO2009082846A1 (fr) 2007-12-28 2009-07-09 Topharman Shanghai Co., Ltd. Dérivé hydroxyle de la capécitabine, ses procédés de préparation et ses utilisations pour préparer la capécitabine
EP2096114A1 (en) 2008-02-27 2009-09-02 Bayer CropScience AG Insecticidal Derivates of Substituted Phosphorylated Phenylalkyl Iminooxazolines and Iminothiazolines
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010027326A1 (en) 2008-09-03 2010-03-11 Nanyang Technological University Peptide nucleic acid monomers and oligomers
EP2350296A4 (en) 2008-11-17 2013-04-03 Enzon Pharmaceuticals Inc BRANCHED CATIONIC LIPIDS FOR THE SYSTEM FOR INTRODUCING NUCLEIC ACIDS
EP2393472B1 (en) 2008-12-05 2019-06-05 NanoMed Holdings Pty Ltd Amphiphile prodrugs
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
CN101525361B (zh) 2009-04-21 2010-11-17 济南圣鲁金药物技术开发有限公司 基于吉西他滨结构的前药及其合成方法及应用
CN101875680B (zh) 2009-04-28 2012-07-25 上海信旗医药科技有限公司 一种核苷类化合物及其制备方法和应用
JO3027B1 (ar) 2009-05-14 2016-09-05 Janssen Products Lp نيوكليوسيدات يوراسيل سبيرواوكسيتان
CN101921303A (zh) 2009-06-09 2010-12-22 曾慧慧 苯并异硒唑酮二氟胞苷类化合物及其制备方法和其用途
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
CN102939291B (zh) 2010-04-14 2016-09-07 加利福尼亚大学董事会 用于病毒感染治疗的具有降低的毒性的膦酸酯
CN102351931B (zh) 2010-09-07 2014-01-22 河南省科学院高新技术研究中心 嘧啶核苷衍生物、合成方法及其在制备抗肿瘤、抗病毒药物中的应用
US20120070411A1 (en) 2010-09-22 2012-03-22 Alios Biopharma, Inc. Substituted nucleotide analogs
US20120142627A1 (en) 2010-12-06 2012-06-07 Emory University Monophosphate prodrugs of dapd and analogs thereof
US8772474B2 (en) 2010-12-22 2014-07-08 Alios Biopharma, Inc. Cyclic nucleotide analogs
CN102219817A (zh) 2011-04-12 2011-10-19 连云港杰瑞药业有限公司 活性偶联剂用于氟化嘧啶化合物烷氧羰酰化的方法
SI2827875T1 (sl) 2012-03-21 2019-04-30 Alios Biopharma, Inc. Substituirani nukleozidi, nukleotidi in njihovi analogi
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
PT2861611T (pt) 2012-05-25 2016-10-11 Janssen Sciences Ireland Uc Nucleósidos de espirooxetano de uracilo
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
US9872919B2 (en) 2012-09-19 2018-01-23 The Research Foundation For The State University Of New York Prodrugs for selective anticancer therapy
ES2674980T3 (es) 2012-10-08 2018-07-05 Idenix Pharmaceuticals Llc Análogos de 2'-cloro nucleósidos para infección por VHC
EP2909209B1 (en) 2012-10-17 2022-08-03 Merck Sharp & Dohme LLC 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
US9227990B2 (en) 2012-10-29 2016-01-05 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
US9447137B2 (en) 2012-11-07 2016-09-20 Nucorion Pharmaceuticals, Inc. Substituted gemcitabine aryl amide analogs
JP2016501200A (ja) 2012-11-19 2016-01-18 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. ウイルス性疾患を処置するための2−アルキニル置換ヌクレオシド誘導体
US9243022B2 (en) 2012-12-21 2016-01-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2014124430A1 (en) 2013-02-11 2014-08-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2014145207A1 (en) 2013-03-15 2014-09-18 Ohio State Innovation Foundation Substituted gemcitabine bicyclic amide analogs and treatment methods using same
WO2014204831A1 (en) 2013-06-18 2014-12-24 Merck Sharp & Dohme Corp. Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP3074399A1 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
JP2017504572A (ja) 2013-11-27 2017-02-09 アイデニクス・ファーマシューティカルズ・エルエルシー 肝臓癌治療のためのヌクレオチド類
WO2015134334A1 (en) 2014-03-03 2015-09-11 Suo Zucai Gemcitabine analogs
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
AU2015265607A1 (en) 2014-05-28 2016-11-17 Idenix Pharmaceuticals Llc Nucleoside derivatives for the treatment of cancer
WO2017019581A1 (en) 2015-07-29 2017-02-02 Merck Sharp & Dohme Corp. Process for making phosphorus-containing nucleoside prodrug compounds
JP6743135B2 (ja) 2015-09-02 2020-08-19 アッヴィ・インコーポレイテッド 抗ウィルス性テトラヒドロフラン誘導体
CN106554382B (zh) 2015-09-29 2019-12-03 四川科伦博泰生物医药股份有限公司 核苷磷酰胺类化合物及其制备方法和药物中的应用
US20200179428A1 (en) 2016-06-20 2020-06-11 Merck Sharp & Dohme Corp. Cyclic phosphate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP3471737B1 (en) 2016-06-20 2025-06-04 Merck Sharp & Dohme LLC Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases
US11364257B2 (en) 2016-06-24 2022-06-21 Emory University Phosphoramidates for the treatment of hepatitis B virus
CN106317116A (zh) 2016-08-19 2017-01-11 张红利 磷酰胺核苷类化合物及其药学上可接受的盐与应用、药物组合物
US20190365788A1 (en) 2016-11-21 2019-12-05 Idenix Pharmaceuticals Llc Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases
US10899786B2 (en) 2016-12-23 2021-01-26 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nucleoside phosphate compound and preparation method and use thereof
CN111491634A (zh) 2017-07-31 2020-08-04 詹纽瑞治疗公司 有机磷酸酯衍生物
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
CN109956986B (zh) 2017-12-22 2021-04-27 浙江柏拉阿图医药科技有限公司 肝递送吉西他滨前体药物核苷环磷酸酯化合物及应用
AU2019207626B2 (en) 2018-01-10 2023-10-05 Nucorion Pharmaceuticals, Inc. Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
US11427550B2 (en) * 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
AU2019227986A1 (en) 2018-03-02 2020-10-08 January Therapeutics, Inc. Nanoparticle compositions
WO2020154917A1 (en) 2019-01-29 2020-08-06 Minghui Pharmaceutical (Shanghai) Limited Phosphate and phosphonate based compounds of 6-thio-2'-deoxyguanosine as anti-cancer agents
MX428883B (es) 2019-04-22 2025-11-13 Ligand Pharm Inc Compuestos ciclicos de fosfato
WO2020227132A1 (en) 2019-05-03 2020-11-12 Terns, Inc. Compounds for treating cancer
WO2021011692A1 (en) 2019-07-17 2021-01-21 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
EP4143199B1 (en) * 2020-04-21 2025-11-19 Ligand Pharmaceuticals, Inc. Nucleotide prodrug compounds
WO2022086858A1 (en) 2020-10-19 2022-04-28 Aptinyx Inc. Methods of treating post-traumatic stress disorder and related conditions
JP7699205B2 (ja) 2020-10-21 2025-06-26 リガンド・ファーマシューティカルズ・インコーポレイテッド 抗ウイルスプロドラッグ化合物
US20240294565A1 (en) 2021-05-17 2024-09-05 Ligand Pharmaceuticals Incorporated Unnatural configuration nucleotide prodrug compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007094135A1 (ja) 2006-02-15 2007-08-23 Gifu University オリゴヌクレオチド誘導体及びその利用
WO2014043380A1 (en) 2012-09-14 2014-03-20 Ligand Pharmaceuticals Incorporated Novel nucleotide prodrug compounds and use
WO2016138026A1 (en) 2015-02-25 2016-09-01 Ligand Pharmaceuticals, Inc. Gemcitabine derivatives
US20190015432A1 (en) 2017-07-13 2019-01-17 Emory University Lipid Disulfide Prodrugs and Uses Related Thereto
WO2019143860A1 (en) 2018-01-19 2019-07-25 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds

Also Published As

Publication number Publication date
US20230159574A1 (en) 2023-05-25
US12552820B2 (en) 2026-02-17
JP2026032020A (ja) 2026-02-25
JP2023522866A (ja) 2023-06-01
WO2021216431A1 (en) 2021-10-28
CN115768778A (zh) 2023-03-07
EP4139319A1 (en) 2023-03-01
EP4139319A4 (en) 2024-06-19

Similar Documents

Publication Publication Date Title
TWI838355B (zh) 5-氟尿嘧啶化合物
JP7661235B2 (ja) 環状リン酸エステル化合物
TWI870583B (zh) 核苷酸前藥化合物
JP7181938B2 (ja) ホスホロ(ン)アミダートアセタールおよびホスファ(ホナ)ートアルセタール化合物
US10435429B2 (en) 5-fluorouridine monophosphate cyclic triester compounds
JP7699205B2 (ja) 抗ウイルスプロドラッグ化合物
JP2026032020A (ja) ベンジルオキシリン酸エステル(ホスホン酸エステル)化合物
JP7625542B2 (ja) 環状デオキシリボヌクレオチド化合物
RU2836016C2 (ru) Циклические дезоксирибонуклеотидные соединения
HK40105750A (en) Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
HK40108726A (en) Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
HK40063264A (en) Cyclic deoxyribonucleotide compounds
HK40063264B (en) Cyclic deoxyribonucleotide compounds

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240329

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250530

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251117

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260316

R150 Certificate of patent or registration of utility model

Ref document number: 7836769

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150